nature portfolio

		Tian Hua,	Laura H	l. Heitman,	Mario v	/an (de

Corresponding author(s): Stelt, Pal Pacher, Zhi-Jie Liu

Last updated by author(s): Feb 15, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

~				
\ 1	ta:	tic:	tπ	\sim

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So	ftware and code

Policy information about availability of computer code

Data collection

Cryo-EM single particle data was automatically collected on the Titan Krios using serialEM 3.7.3.

Data analysis

CryoSPARC3.3.2, Phenix1.20.1-4487, COOT0.9.6, UCSF Chimera1.16, PyMOL 2.5.2, GraphPad Prism 6.0 and 9.0, ChemDraw 19.0

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The atomic coordinates for CB2-APD371-Gi-scFv16, CB2-CP55940-Gi-scFv16, CB2-HU308-Gi-scFv16 and CB2-LEI-102-Gi-scFv16 have been deposited in the Protein Data Bank with the accession codes 8GUQ, 8GUR, 8GUS and 8GUT. The EM maps for CB2-APD371-Gi-scFv16, CB2-CP55940-Gi-scFv16, CB2-HU308-Gi-scFv16 and CB2-LEI-102-Gi-scFv16 have been deposited in EMDB with the codes EMD-34276, EMD-34277, EMD-34278 and EMD-34279, respectively.

Human rese	arch parti	cipants				
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.				
Reporting on sex and gender		N/A				
Population characteristics		N/A				
Recruitment		N/A				
Ethics oversight		N/A				
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.				
Tiple opp	-:£:					
Field-spe		. 9				
	ne below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
Life sciences	В	ehavioural & social sciences				
For a reference copy of t	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
1:6:						
Lite scier	ices sti	udy design				
All studies must dis	close on these	points even when the disclosure is negative.				
Sample size	Sample sizes were determined by the current standard for in vitro binding and signaling experiments. Receptor expression experiments (ELISA) were carried out in two independent experiments and each datapoint was measured in quintuplicate. Binding and functional experiments were performed in at least three independent experiments performed in duplicate. These numbers are deemed large enough to identify variations between drug treatment or mutants as based on other studies with similar methodology. For cryo-EM experiment, the accurate micrographs and particles were included in the Method.					
Data exclusions	No data were e	No data were excluded.				
Replication	Experiments were repeated as described above and in the manuscript sections methods or figure legends.					
Randomization	Compounds were tested in dose-response curves on membrane fractions. All data was normalized to baseline/vehicle conditions within the plate and averaged among replicates. Compound or receptor effects were randomized on the plate to avoid 'plate effects'. Wild-type controls were always included on the plate in experiments with mutant receptors.					
Blinding	There was no blinding in the study, the experiments for cryo-EM, in vitro and in vivo studies do not need blinding due to the purposes of the experiments.					
We require informatis system or method list Materials & expended in the system of method list Materials &	perimental s ne study cell lines ogy and archaeol d other organism	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging				

Antibodies

Antibodies used

Monoclonal ANTI-FLAG® M2 antibody (Sigma Aldrich, #F3165), Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L)(Jackson ImmunoResearch Laboratories, #115-035-003)

Validation

The former antibody has been validated for use in ELISA previously (https://www.sigmaaldrich.com/HK/zh/product/sigma/f3165); The later antibody has been validated for use in ELISA previously (https://www.jacksonimmuno.com/catalog/products/115-035-003)

Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

Cell line source(s)

Spodoptera frugiperda (Sf9) insect cells were used for CB2R-Gi co-expression for cryo-EM studies. Spodoptera frugiperda (Sf9) cells were a gift from Beili Wu lab from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Human embryonic kidney 293 T (HEK293T; female) cells for transfections were obtained from ATCC and CHO cells stably expressing hCB2R (CHOK1_hCB2bgal; PathHunter EA Parental Cell line, female) were obtained from DiscoverX.

Authentication

Cells were not further authenticated. Expression of wild-type or mutant CBR after transfection was authenticated by ELISA using the antibodies described above.

Mycoplasma contamination

All cells have been tested as negative for mycoplasma contamination.

Commonly misidentified lines (See <u>ICLAC</u> register)

No commonly misidentified cell lines were used.

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals

Ten to twelve-week-old male/female C57BL/6J mice from The Jackson Laboratory (Bar Harbor, ME, USA).

Wild animals

No wild animals were used in this study.

Reporting on sex

Both male and female mice were used according to NIH guidelines

Field-collected samples

no

Ethics oversight

All animal experiments reported in this manuscript complied with the National Institutes of Health "Guide for the Care and Use of Laboratory Animals" (NIH publication 86-23 revised 1985) and were approved by the Institutional Animal Care and Use Committee of the National Institute on Alcohol Abuse and Alcoholism (Bethesda, MD). Animals were kept in the institute's designated animal facility under constant temperature (22 ± 2 °C) and humidity, with 12-hour alternating light and dark cycles.

Note that full information on the approval of the study protocol must also be provided in the manuscript.